Unknown

Dataset Information

0

The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.


ABSTRACT: Co-inhibitory receptors are important regulators of T-cell function that define the balance between tolerance and autoimmunity. The immune regulatory function of co-inhibitory receptors, including CTLA-4, PD-1, TIM-3, TIGIT, and LAG-3, was first discovered in the setting of autoimmune disease models, in which their blockade or deficiency resulted in induction or exacerbation of the disease. Later on, co-inhibitory receptors on lymphocytes have also been found to influence outcomes in tumor and chronic viral infection settings. These receptors suppress T-cell function in the tumor microenvironment (TME), thereby making the T cells dysfunctional. Based on this observation, blockade of co-inhibitory receptors (also known as checkpoint molecules) has emerged as a successful treatment option for a number of human cancers. However, severe autoimmune-like side effects limit the use of therapeutics that block individual or combinations of co-inhibitory receptors for cancer treatment. In this review we provide an overview of the role of co-inhibitory receptors in autoimmunity and anti-tumor immunity. We then discuss current approaches and future directions to leverage our knowledge of co-inhibitory receptors to target them in tumor immunity without inducing autoimmunity.

SUBMITTER: Schnell A 

PROVIDER: S-EPMC7118128 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3620843 | biostudies-literature
| S-EPMC5338458 | biostudies-literature
| S-EPMC7112810 | biostudies-literature
| S-EPMC6520700 | biostudies-literature
| S-EPMC6331903 | biostudies-literature
| S-EPMC7137337 | biostudies-literature
| S-EPMC7473878 | biostudies-literature
| S-EPMC3039848 | biostudies-other
| S-EPMC3386643 | biostudies-literature
| S-EPMC8038660 | biostudies-literature